Korro Bio, Inc. Net Income
Korro Bio, Inc. (KRRO) reported Net Income of -$18.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Korro Bio, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$18.92M.
- Korro Bio, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$19.63M.
- Korro Bio, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$50.04M.
- Korro Bio, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$18.06M.
- Korro Bio, Inc. net income (loss) attributable to parent for fiscal 2022 was -$58.03M.
- Korro Bio, Inc. net income (loss) attributable to parent for fiscal 2021 was -$84.69M.
- Korro Bio, Inc. net income (loss) attributable to parent for fiscal 2020 was -$26.51M.
- Korro Bio, Inc. net income (loss) attributable to parent for fiscal 2019 was -$18.75M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$18.92M 10-Q · filed 2026-08-06 | -$38.54M 10-Q · filed 2026-08-06 | -$88.58M derived: sum of 3 quarters · filed 2026-08-06 | -$106.64M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$19.63M 10-Q · filed 2026-08-06 | -$69.67M derived: sum of 2 quarters · filed 2026-08-06 | -$87.73M derived: sum of 3 quarters · filed 2026-08-06 | -$113.50M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$50.04M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-16 | -$68.10M derived: sum of 2 quarters · filed 2026-04-16 | -$93.87M derived: sum of 3 quarters · filed 2026-08-06 | -$117.26M DEF 14A · filed 2026-04-16 | ||||
| 2025-09-30 | -$18.06M 10-Q · filed 2025-11-12 | -$43.83M derived: sum of 2 quarters · filed 2026-08-06 | -$67.22M 10-Q · filed 2025-11-12 | -$88.42M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$25.77M 10-Q · filed 2026-08-06 | -$49.16M 10-Q · filed 2026-08-06 | -$70.36M derived: sum of 3 quarters · filed 2026-08-06 | -$91.36M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$23.39M 10-Q · filed 2026-08-06 | -$44.59M derived: sum of 2 quarters · filed 2026-08-06 | -$65.58M derived: sum of 3 quarters · filed 2026-08-06 | -$87.41M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-12-31 | -$21.20M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-16 | -$42.20M derived: sum of 2 quarters · filed 2026-04-16 | -$64.02M derived: sum of 3 quarters · filed 2026-04-16 | -$83.58M DEF 14A · filed 2026-04-16 | ||||
| 2024-09-30 | -$21.00M 10-Q · filed 2025-11-12 | -$42.83M derived: sum of 2 quarters · filed 2025-11-12 | -$62.38M 10-Q · filed 2025-11-12 | -$87.81M derived: sum of 4 quarters · filed 2026-04-16 | ||||
| 2024-06-30 | -$21.83M 10-Q · filed 2025-11-12 | -$41.38M 10-Q · filed 2025-08-12 | -$66.81M derived: sum of 3 quarters · filed 2026-04-16 | -$85.30M derived: sum of 4 quarters · filed 2026-04-16 | ||||
| 2024-03-31 | -$19.56M 10-Q · filed 2025-11-12 | -$44.98M derived: sum of 2 quarters · filed 2026-04-16 | -$63.48M derived: sum of 3 quarters · filed 2026-04-16 | -$81.12M derived: sum of 4 quarters · filed 2026-04-16 | ||||
| 2023-12-31 | -$25.43M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-16 | -$43.92M derived: sum of 2 quarters · filed 2026-04-16 | -$61.57M derived: sum of 3 quarters · filed 2026-04-16 | -$81.17M DEF 14A · filed 2026-04-16 | ||||
| 2023-09-30 | -$18.49M 10-Q · filed 2024-11-12 | -$11.61M 10-Q · filed 2023-11-02 | -$36.14M derived: sum of 2 quarters · filed 2024-11-12 | -$55.75M 10-Q · filed 2024-11-12 | -$41.95M 10-Q · filed 2023-11-02 | -$49.56M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$17.65M 10-Q · filed 2024-11-12 | -$10.80M 10-Q · filed 2023-08-10 | -$37.25M 10-Q · filed 2024-08-13 | -$30.34M 10-Q · filed 2023-08-10 | -$31.07M derived: sum of 3 quarters · filed 2024-11-12 | -$50.62M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-03-31 | -$19.61M 10-Q · filed 2024-11-12 | -$19.54M 10-Q · filed 2023-05-12 | -$13.42M derived: sum of 2 quarters · filed 2024-11-12 | -$32.97M derived: sum of 3 quarters · filed 2024-11-12 | -$54.25M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2022-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$13.36M derived: sum of 2 quarters · filed 2024-03-26 | -$34.65M derived: sum of 3 quarters · filed 2024-03-26 | -$58.03M 10-K · filed 2024-03-26 | -$81.58M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | -$19.55M 10-Q · filed 2023-11-02 | -$40.83M derived: sum of 2 quarters · filed 2023-11-02 | -$64.22M 10-Q · filed 2023-11-02 | -$85.72M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | -$21.29M 10-Q · filed 2023-08-10 | -$44.67M 10-Q · filed 2023-08-10 | -$66.17M derived: sum of 3 quarters · filed 2023-08-10 | -$91.33M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$23.39M 10-Q · filed 2023-05-12 | -$44.89M derived: sum of 2 quarters · filed 2023-05-12 | -$70.04M derived: sum of 3 quarters · filed 2023-05-12 | -$87.70M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | -$21.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$46.66M derived: sum of 2 quarters · filed 2023-03-10 | -$64.31M derived: sum of 3 quarters · filed 2023-03-10 | -$84.69M 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | -$25.16M 10-Q · filed 2022-11-08 | -$42.81M derived: sum of 2 quarters · filed 2022-11-08 | -$63.19M 10-Q · filed 2022-11-08 | -$73.42M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$17.66M 10-Q · filed 2022-08-09 | -$38.03M 10-Q · filed 2022-08-09 | -$48.26M derived: sum of 3 quarters · filed 2022-08-09 | -$53.60M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$20.38M 10-Q · filed 2022-05-04 | -$30.61M derived: sum of 2 quarters · filed 2022-05-04 | -$35.95M derived: sum of 3 quarters · filed 2022-05-04 | -$41.97M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | -$10.23M 10-K · filed 2021-03-29 | -$15.57M derived: sum of 2 quarters · filed 2021-11-15 | -$21.60M derived: sum of 3 quarters · filed 2021-11-15 | -$26.51M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$5.34M 10-Q · filed 2021-11-15 | -$11.37M derived: sum of 2 quarters · filed 2021-11-15 | -$16.28M 10-Q · filed 2021-11-15 | -$21.77M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | -$6.03M 10-Q · filed 2021-08-12 | -$10.94M 10-Q · filed 2021-08-12 | -$16.43M derived: sum of 3 quarters · filed 2021-08-12 | -$17.01M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | -$4.91M 10-Q · filed 2021-05-13 | -$10.41M derived: sum of 2 quarters · filed 2021-05-13 | -$10.98M derived: sum of 3 quarters · filed 2021-05-13 | -$17.83M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | -$5.49M 10-K · filed 2021-03-29 | -$6.07M derived: sum of 2 quarters · filed 2021-03-29 | -$12.92M derived: sum of 3 quarters · filed 2021-03-29 | -$18.75M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | -$575.00K 10-K · filed 2021-03-29 | -$7.43M derived: sum of 2 quarters · filed 2021-03-29 | -$13.25M 10-Q · filed 2020-11-16 | -$18.70M derived: sum of 4 quarters · filed 2021-03-29 | ||||
| 2019-06-30 | -$6.85M 10-K · filed 2021-03-29 | -$12.68M 10-Q · filed 2020-08-12 | -$18.13M derived: sum of 3 quarters · filed 2021-03-29 | -$23.26M derived: sum of 4 quarters · filed 2021-03-29 | ||||
| 2019-03-31 | -$5.83M 10-K · filed 2021-03-29 | -$11.27M derived: sum of 2 quarters · filed 2021-03-29 | -$16.41M derived: sum of 3 quarters · filed 2021-03-29 | -$20.84M derived: sum of 4 quarters · filed 2021-03-29 | ||||
| 2018-12-31 | -$5.45M 10-K · filed 2020-03-26 | -$10.58M derived: sum of 2 quarters · filed 2020-03-26 | -$15.02M derived: sum of 3 quarters · filed 2020-03-26 | -$19.17M 10-K · filed 2020-03-26 | ||||
| 2018-09-30 | -$5.14M 10-K · filed 2020-03-26 | -$9.57M derived: sum of 2 quarters · filed 2020-03-26 | -$13.72M 10-Q · filed 2019-11-18 | |||||
| 2018-06-30 | -$4.44M 10-K · filed 2020-03-26 | -$8.59M derived: sum of 2 quarters · filed 2020-03-26 | ||||||
| 2018-03-31 | -$4.15M 10-K · filed 2020-03-26 | |||||||
| 2017-12-31 | -$20.24M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |